Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. NYSE:NSRX (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intran…